|
|
 |
|
Viewing report
|
|
|
|
Market Dynamics 2000: Allergic Rhinitis: Effects of Major Patent Expiries On An Expanding Market
Datamonitor, Jan 2001
The imminent patent expiry of Schering-Plough’s Claritin will open up the market, allowing the entry of several key new players including Merck and Novartis and a move towards more preventative therapies. Schering-Plough will counter the significant loss in market share driven by the patent expiry of Claritin with the launch of two new allergy products, ensuring interesting competitive activity in the allergic rhinitis market from 2001 onwards. Datamonitor''s report, ‘Market Dynamics 2000: Allergic Rhinitis’ provides an in-depth strategic analysis of the allergic rhinitis market to 2007. The report provides comprehensive coverage of the seven major pharmaceutical markets (the US, Japan, France, Germany, Italy, Spain, and the UK) with an in-depth analysis of the current and future commercial attractiveness of the allergic rhinitis market.
Customers who bought this item also bought
Commercial and Pipeline Insight: Allergic Rhinitis
Commercial and Stakeholder Perspectives: Allergic Rhinitis - Is There Life After Claritin?
Treatment Algorithms 2001: Allergic Rhinitis - Unlocking the Real Patient Potential
Strategic Perspectives: Allergic Rhinitis - Impact of a blockbuster going bust
Drugs of Tomorrow 2000: Allergic Rhinitis - New Drug Classes, Towards Total Disease Management
Allergic Rhinitis Opinion Leader Forum, 2002
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Br. Holdings Corporation
Br Malls Participacoes Sa
Rigels Allergic Rhinitis Candidate - R112
Pipeline Insight: Asthma, Copd and Allergic Rhinitis - The Needs of Severe Patients Must be Addressed
Pipeline Insight: Asthma/COPD/Allergic Rhinitis - As Patents Expire, Novel Combinations Inspire
|
|
|
|
